摘要
鲍曼不动杆菌已经成为院内感染的主要病原体,并且随着多重耐药鲍曼不动杆菌(MDRAB)的增加,对它的治疗已经受到重视。本文着重介绍了针对多重耐药鲍曼不动杆菌的抗生素,药物联用仍是有效方法。新型肽类抗生素如人β-防卫素2、(LLKK)2C和[E4K]alyteserin-1c等具有抗菌活性高、副作用小等优点,具有很好的应用前景。
Acinetobacter baumannii had emerged as a major pathogen causing hospital infections. With the increase of multidrug-resistant Acinetobacter baumannii (MDRAB), there is a clear need to seek therapeutic approaches. Antibacterial agents for MDRAB infections were mainly introduced in this article. Combination of antibiotics was still the effective method. New peptide antibiotics such as Human β-defensin 2, (LLKK)2C and [E4K] alyteserin-1c could hopefully be ideal antibacterial agents with advantages of potent antibacterial activity and little side effects.
出处
《国外医药(抗生素分册)》
CAS
2013年第5期193-196,共4页
World Notes on Antibiotics
关键词
MDRAB
耐药
联合用药
抗菌肽
MDRAB resistance combination ofdrugs antimicrobial peptides